Latest Conference Articles

At a friendly debate held at the European Hematology Association 2024 Congress, hemophilia experts argued for and against wider access to gene therapy for patients living with the condition.

Ryan Jacobs, MD, of Atrium Health Levine Cancer Institute, explains that the phase 2 CAPTIVATE study's fixed-duration treatment cohort shows long-term progression-free survival for patients with chronic lymphocytic leukemia (CLL) who received the first-line treatment of ibrutinib and venetoclax.

This investigation used data from The US Oncology Network on trends in lung cancer stage when patients present for care.

The results of the 3-year follow-up show meaningful improvement in overall survival (OS) and progression-free survival (PFS) for tislelizumab plus chemotherapy compared with placebo plus chemotherapy.

Abstracts presented at the 2024 European Hematology Association Congress deliver results on regimens involving venetoclax for chronic lymphocytic leukemia (CLL).

Results presented at the 2024 European Hematology Association Congress suggest that chimeric antigen receptor (CAR) T-cell therapy can be feasibly and safely delivered in the outpatient setting as treatment for lymphoma.

Brian Koffman, MDCM, DCFP, FCFP, DABFP, MSEd, of CLL Society, details the comprehensive multidisciplinary support for patients with chronic lymphocytic leukemia (CLL) at the European Hematology Association (EHA) 2024 Congress.

Marta Rodríguez Martínez, PhD, sustainability officer of the European Molecular Biology Laboratory, highlights the primary sources of scientific research waste and how to reduce them.

At a YoungEHA session at the 2024 European Hematology Association (EHA) Congress, speakers discussed the prevalence of waste in laboratories, research, and clinical practice, as well as ways attendees can effect change for a more sustainable future.

One patient died during this study, which used PET/CT, flow cytometry, and next-generation sequencing to define measurable residual disease negativity.

The SLEEP 2024 Annual Meeting featured talks on numerous topics throughout the 5-day meeting, including sleep inequities, narcolepsy, and mental health’s association with sleep.

The TRITON study is evaluating tremelimumab/durvalumab/chemotherapy vs pembrolizumab/chemotherapy in non–small lung cancer (NSCLC) with STK11 and/or KEAP1 and/or KRAS mutations.

During the CMS Health Equity Conference, health care leaders shared groundbreaking strategies to integrate health equity into value-based care models, aiming to enhance patient outcomes and reduce costs.

The global burden of liver cancer is rising, and public health efforts for prevention, vaccination, and treatment to address underlying etiologies are needed, according to research presented at ASCO 2024.

Findings from ASCO 2024 suggest deruxtecan (T-DXd) may become a preferred first-line treatment for patients with hormone receptor (HR)-positive, HER2-low metastatic breast cancer that progressed after endocrine therapy.

Experts share what they are looking forward to most at this year's European Hematology Association (EHA) Congress.

Melissa Jones, MD, shares insights into recent artificial intelligence (AI) innovations in the realm of sleep studies.

Several experts that we spoke with for ASCO 2024 share their thoughts on why the American Society of Clinical Oncology annual meeting is so important to the field of oncology.

The 2024 European Hematology Association (EHA) Congress, convening virtually and in Madrid, Spain, from June 13-16, 2024, will feature practice-changing findings in hematology and oncology, as well as ample networking opportunities and conversations about the future of the field.

Speakers at SLEEP 2024, the annual meeting of The American Academy of Sleep Medicine and Sleep Research Society, share their favorite parts of the conference.

Coverage of a session on antibody drug conjugates from the 2024 American Society of Clinical Oncology Annual Meeting.

Surya Bhatt, MD, MSPH, of the University of Alabama at Birmingham, explained the phase 3 BOREAS and NOTUS trials demonstrated comparable safety profiles for dupilumab in treating patients with chronic obstructive pulmonary disease (COPD).

During the CMS Health Equity conference, the “Implementing Health Equity Through Value-Based Care for People in Medicare” session featured a series of expert speakers who shared insights on pioneering strategies designed to advance health equity.

Allison Brager, PhD, neuroscientist, Walter Reed Army Institute of Research, discusses the interplay between physical exercise and circadian rhythms in improving cardiovascular health.

Ron Grunstein, MD, PhD, head of sleep and circadian research, Woolcock Institute of Medical Research, shares findings from a phase 1b study on the use of a novel orexin agonist in patients with narcolepsy type 1.

Posters presented at SLEEP 2024 found reduced total sleep time among adolescents on weeknights, leading to less total sleep, as well as a link between lower sleep duration and poor mental health.

Slowing the loss of ambulation in patients with Duchenne muscular dystrophy (DMD) may also mitigate worsening disease burden and overall function, according to a pair of posters presented at ISPOR 2024.

A session at the SLEEP 2024 Annual Meeting discussed the various inequities in sleep that persist in individuals who are incarcerated, attend university, or work at hospitals.